Introduction
Tuberculosis (TB) is an AIDS-defining illness, and HIV is the single strongest risk factor for progression from latent TB infection to active TB disease [1, 2] . Antiretroviral therapy (ART) for HIV infection can reduce the risk for progression from latent to active TB, rates of TB relapse, and risk of death from TB [3] [4] [5] . Therefore, knowledge of a patient's HIV status is essential to effectively manage both TB and HIV infections, as well as prevent future cases of TB.
From 2001 to 2007, there were over 7,200 cases of TB verified by New York City (NYC) [6] . NYC TB cases account for approximately 10 % of all TB cases in the United States. Nationally, 7 % of TB patients reported to the Centers for Disease Control and Prevention (CDC) in 2007 were HIV-infected; in NYC, 13 % of TB patients were HIV-infected [6, 7] .
In 1989, the CDC recommended that all TB patients be tested for HIV infection [8] . Nationally, the number of TB patients with an HIV test result increased from 35 % in 1993 to 68 % in 2003. However, in 2007, 30 % of TB patients in the US still did not have an HIV test result; 22 % of TB patients were not offered an HIV test, and 8 % refused HIV testing [7] .
Most evaluations of HIV testing of TB patients in the US and other developed countries were conducted in the mid-1990s. TB patients in Los Angeles and Canada with traditional HIV risk factors were more likely to have an HIV test result on record than other patients [9] [10] [11] . In North Carolina, providers were more likely to offer HIV testing to patients who were non-Hispanic black, users of non-injection drugs, or living in a high HIV incidence county; patients who were male, non-Hispanic black, or users of non-injection drugs were more likely to accept HIV testing [12] . More recently in the mid-2000s, providers in London were more likely to offer HIV testing to younger, foreign-born TB patients; male and younger patients were more likely to accept HIV testing [13] .
Adherence to national TB diagnostic and treatment guidelines varies by TB medical provider type [14] [15] [16] [17] . Public clinics and hospitals serve as safety net providers for many publically insured or uninsured, often minority, populations [18] . As these populations are also at greatest risk for HIV infection, public providers may be more aware of recommendations for TB and HIV medical care [19, 20] . In Los Angeles in 1993, HIV testing was more common among patients who initially sought care from public providers than private providers (69 vs 44 %) [11] . Recent data exploring the relationship between the type of TB medical provider and adherence to HIV testing recommendations are predominately descriptive and did not differentiate a provider's failure to offer an HIV test and a patient's test refusal [21] .
This study examines if TB patients of private medical providers have varying HIV testing practices than TB patients of non-private medical providers in NYC during the ART era (2001) (2002) (2003) (2004) (2005) (2006) (2007) . Two specific hypotheses are posited: (1) private TB providers are less likely to offer HIV testing to their patients than public TB providers, and (2) when offered HIV testing, patients of private TB providers are more likely to refuse HIV testing than patients of public medical providers.
Methods
Patients included in this analysis consisted of all active, laboratory-confirmed TB cases verified by the NYC Department of Health and Mental Hygiene (DOHMH) Bureau of Tuberculosis Control between January 1, 2001 and December 31, 2007. Patients were excluded if they were diagnosed with TB at death (n = 149), under the age of 18 years (n = 417), resided outside NYC at diagnosis (n = 6), or sought TB care outside of NYC (n = 456). Since the HIV testing outcome under study was a cumulative measure that incorporates all HIV testing encounters during the course of TB treatment, patients who failed to complete TB treatment were also excluded from analysis (n = 1,066). An additional 46 individuals with missing HIV test information were excluded, resulting in a final sample size of 5,172 TB patients. No statistical differences were observed in the demographics of patients included or excluded by the complete case analysis. Data used in this study were obtained from the TB surveillance registry, which includes data from standardized patient interviews and chart reviews.
HIV Testing Protocol for TB Patients
In the TB surveillance registry, HIV testing status was categorized as: HIV-infected, HIV-uninfected, indeterminate test result, pending result, not offered HIV testing, and refused HIV testing. (Fig. 1) .
A patient's HIV status was first obtained through patient self-report to medical staff, patient chart review, or designation on the initial TB report. TB patients who selfreported being HIV-infected were confirmed through a documented positive and confirmed HIV antibody test. TB patients who self-reported as HIV-uninfected were confirmed via documentation of a negative HIV test performed within 1 year of TB diagnosis.
Per DOHMH protocol, all patients who had an unknown HIV status at TB diagnosis or who were unable to provide documentation of their self-reported HIV status should be offered an HIV test. Patients who accepted HIV testing were tested using an enzyme-linked immunosorbent assay or a rapid HIV antibody test with confirmation of reactive results via Western blot. All test results were documented in the TB surveillance registry. Patients who refused HIV testing were re-offered testing during the course of treatment.
Exposure Assessment
Providers who supplied care to NYC TB patients (''TB providers'') were dichotomized as ''private'' (exposed) or ''public'' (unexposed) for the purpose of this study. ''Private'' providers included private physician offices, private hospitals, and nursing homes. All other TB providers were categorized as non-private or ''public'' providers. ''Public'' providers included DOHMH public chest clinics, Health and Hospitals Corporation (HHC) facilities (publicly financed inpatient and outpatient facilities), and the Veteran's Administration (VA). HHC and VA facilities were categorized as ''public'' because their patients are demographically similar to that of public NYC DOHMH chest centers and they accept patients regardless of their ability to pay [22, 23] . Only data regarding a patient's first and last TB medical provider were available for this analysis. Outcome Assessment
Two primary outcomes were assessed in this study: the offer of an HIV test to a TB patient and the refusal of HIV testing by the TB patient.
In the analysis of the first outcome, patients were categorized as ''not offered HIV testing'' or ''offered HIV testing''. Patients who were ''not offered HIV testing'' were documented as such in the TB surveillance registry and lacked a confirmed HIV test result. Patients who were ''offered HIV testing'' included patients who either refused HIV testing, had a known HIV test result, or had an indeterminate/pending lab result.
In the analysis of the second outcome, patients were categorized as either ''refused HIV testing'' or ''accepted HIV testing''. Patients who were categorized as ''refused HIV testing'' were not tested at any point during the course of TB treatment, as documented in the TB surveillance registry. Patients who accepted HIV testing had a known HIV test result or an indeterminate/pending lab result in the TB surveillance registry.
Patients whose self-reported HIV status was confirmed as either HIV-infected or HIV-uninfected could not be distinguished in the TB registry from patients who received a HIV test during the course of being diagnosed and treated for TB treatment. Patients with confirmed self-reported HIV status were considered to have been successfully tested and were therefore coded as ''offered HIV testing'' in the analysis of HIV test offers and ''accepted HIV testing'' in the analysis of HIV test refusal.
Covariates
Covariates included in this analysis were patient sex (male, female), age (continuous), race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, Asian), birth in the US (yes, no), any history of homelessness (yes, no), substance use (yes, no), TB drug resistance (any, none), and extrapulmonary TB diagnosis (any, none). Patients of other race/ethnicity categorizations (e.g., multiple race or other race, n = 26) were excluded due to small numbers.
Statistical Analyses
Due to the restrictions of the TB surveillance registry, we could not determine which TB provider ordered an HIV test on a patient; only a cumulative measure of a TB patient's HIV status at the completion of TB treatment was available. Therefore, analyses were restricted to crosssectional associations of a patient's type of TB provider and final HIV status at TB treatment completion.
Three regression models were used to assess the association between TB provider type and HIV testing outcomes; each regression model incorporated different assumptions regarding a patient's pattern of contact with TB providers. The Initial Provider Model (Model 1) assumed that the patient's HIV testing encounter occurred during a visit with the first provider from whom the patient sought TB treatment. The Provider Change Model (Model 2) allowed for patients to change their type of TB provider during the course of TB treatment using 3-level, categorical exposure variable: only private providers, only public providers, and a change in the type of provider during treatment based on the first and last TB medical provider documented in the TB surveillance registry. The Directional Provider Change Model (Model 3) accounted for the directionality of provider type changes during the course of TB treatment using a 4-level categorical exposure variable: only private providers, only public providers, change from private to public provider, or change from public to private provider.
The provider's offer of HIV testing to patients was modeled using unconditional logistic regression; patient refusal of HIV 
Results
From 2001 to 2007, 5,172 TB patients in NYC met the eligibility requirements for analysis, nearly 25 % (n = 1,243/5,172) of whom did not successfully complete the HIV testing protocol for TB patients (Fig. 1) . Over half of patients initially engaged in TB care with a private provider (53 %, n = 2,722/5,172); 28.4 % (n = 772/ 2,722) were not tested for HIV during their TB treatment (Table 1) . Among the 47 % of patients initially engaged in TB care with a public provider (n = 2,450/5,172), 18 % (n = 441/ 2,450) were not tested for HIV. Approximately one-third of TB patients changed provider type during the course of TB treatment (32.0 %, n = 1,656/5,172). Only 3 % (n = 162/ 5,172) of TB patients were not offered an HIV test during the course of TB treatment; of these, 103 (64 %) first engaged in TB treatment with a private provider. Nearly one-third (28 %, n = 1,081/5,172) of TB patients who were offered an HIV test subsequently refused HIV testing; 699 (65 %) of these patients first engaged in TB care with a private provider. Over 700 TB patients were HIV-infected (15 %, n = 733/5,172); 377 (51 %) of these first engaged in care with a private TB provider. Among the 3,193 HIV-uninfected patients, 1,541 (48 %) initially visited a private TB provider.
Among patients who were not offered an HIV test, 23 % (n = 37/162) were non-Hispanic white and 17 % (n = 27/ 162) were Hispanic. The majority of patients refusing an HIV test were Asian (52 %, n = 599/1,081), and a high proportion were foreign-born (83 %, n = 899/1,081). Older patients were less likely to be offered an HIV test and accept an HIV test when offered than younger patients.
HIV Test Offers
The relationship between TB provider type and not being offered an HIV test differed by gender (test for interaction p \ 0.10). All results are therefore stratified by gender, even though the same overall direction of the association was observed for both genders.
The Initial Provider Model (Model 1), which examined the cross-sectional association of first TB provider type and failure to offer an HIV test, did not show an association for male TB patients [adjusted odds ratio (aOR) 1.01, 95 % confidence interval (CI) 0.76-1.33; Table 2 ]. Female patients of private providers were less likely to be offered an HIV test during the course of treatment than female patients of public providers, although the association was not statistically significant (aOR 0.78, 95 % CI 0.60-1.02).
The Provider Change Model (Model 2) incorporated the potential for a patient to change TB provider type during the course of treatment. Patients who made any change in provider type during the course of treatment were no more or less likely to be offered an HIV test during the course of treatment than patients who only visited public providers (males: aOR 1.09, 95 % CI 0.73-1.61; females: aOR 1.12, 95 % CI 0.72-1.75; Table 2 ). However, patients who only visited private providers were significantly less likely to be offered an HIV test than patients who only visited public providers (males: aOR 0.46, 95 % CI 0.23-0.90; females: aOR 0.37, 95 % CI 0.19-0.70).
The Directional Provider Change Model (Model 3) examined not only changing provider type during treatment, but also the directionality of provider type change (private to public, or public to private). Male patients who changed from a public provider to a private provider during the course of TB treatment were significantly less likely to be offered an HIV test during treatment (aOR 0.14, 95 % CI 0.05-0.40) than patients who only visited a public provider (Table 2) . Males who changed from a private provider to a public provider during TB treatment were more likely to be offered an HIV test (aOR 1.96, 95 % CI 1.04-3.70) than patients who only visited a public provider. Patients who visited only a private TB provider were over three times less likely to be offered an HIV test as patients who only visited public providers (males: aOR 0.33, 95 % CI 0.15-0.74; females: aOR 0.26, 95 % CI 0.12-0.57).
Refusal of HIV Testing
Similar to what was observed in the evaluation of HIV test offers, the relationship between TB provider type and patient refusal of HIV testing differed by gender; therefore, all results were stratified by gender. However, in the Provider Change and Directional Provider Change Models (Models 2 and 3), the relationship between TB provider In the Directional Provider Change Model (Model 3), substance-using men who changed from a private provider to a public provider were marginally less likely to refuse HIV testing than substance-using men who only visited public providers (aPR 0.65, 95 % CI 0.42-1.01). Among women who did not use substances, those who changed from private to public providers were more likely to refuse HIV testing than those who only visited public providers (aPR 1.27, 95 % CI 1.09-1.47). Among both men and women who did not report substance use, patients who only visited private providers were more likely to refuse HIV testing than patients who only visited public providers (men: aPR 1.26, 95 % CI 0.99-1.60; women: aPR 1.78, 95 % CI 1.43-2.22).
Discussion
HIV testing of TB patients is crucial to the effective clinical management and control of both diseases. However, approximately 30 % of the TB patients in the US do not have an HIV test result on record, predominantly due to providers failing to offer or patients refusing HIV testing [7] . Although the type of TB medical provider (public vs private) has been implicated in the failure to adhere to other clinical guidelines for the diagnosis and treatment of TB, the potential association between a patient's provider type and specific poor HIV testing outcomes (failure of a provider to offer a test, patient refusal of a test) has not been examined in the ART era [14] [15] [16] [17] 21] . This study framed the issue of HIV testing and TB providers within the high TB and HIV incidence area of NYC, focusing on the ART era (2001) (2002) (2003) (2004) (2005) (2006) (2007) .
TB patients who only visited private providers were less likely to be offered HIV testing than individuals who only visited public providers. Private providers may be less aware of HIV testing guidelines, because their general population differs from the population typically portrayed as at-risk for TB and HIV. These providers may not realize the high-HIV risk status of their TB patients or be aware of current HIV testing recommendations [24] [25] [26] . Some private providers may harbor internal HIV-related stigma and may not feel comfortable discussing HIV with their patients [24, [26] [27] [28] .
Among men, changing from private to public provider during the course of TB treatment increased the chances of The association between provider type and patient refusal of HIV testing was weaker than the association between provider type and not being offered an HIV test. Among TB patients who did not report substance use, patients who visited only private providers were more likely to refuse HIV testing than patients who visited only public providers. HIV test acceptance was greater among men than among women, which could be attributed to selfperceived HIV risk if women who do not report substance use do not view themselves as at risk for HIV acquisition. Our observations concur with prior studies that identified higher rates of HIV test refusal among female patients [12, 13, 29] .
Among substance users, however, provider type was generally not associated with refusal of HIV testing. Substance use is considered a risk factor for HIV acquisition, and has been previously associated with HIV test acceptance [12] . Patients who do not use substances and visit private providers may have a lower perceived risk of HIV infection [24, 30] . Additionally, providers may recommend HIV testing more strongly to patients with a history of substance use [24, 28] .
The effects of provider type on HIV testing behaviors were more pronounced for women than for men. The differential impact of changing provider type in men and women could be due to provider beliefs that males are more at risk for HIV than females [24, 26] . Despite the high burden of HIV among men who have sex with men, providers who treat TB patients should be trained to acknowledge that all male and female TB patients are at higher-risk for HIV infection than the general population.
One of the primary limitations of this study is that TB patients may have multiple providers between their first and last providers and this information was not available for this study. Theoretically, every visit with a new provider presents another opportunity for HIV testing. Therefore, if a patient visited more than two TB providers, our analysis may not have identified all HIV testing encounters for that patient. Details regarding each provider's medical specialty were not available; such provider characteristics could influence the provider's comfort level with HIV testing. Additionally, due to small numbers this study was not able to examine whether there were differences between private providers and private hospitals.
Additionally, the date of the patient's HIV testing encounter was not included in the TB Registry. These limitations restrict the analysis to prevalence measures based upon data at the conclusion of a TB treatment.
Patients who do not complete TB treatment may have poor healthcare seeking and adherence behaviors; the exclusion of these persons may underestimate HIV test refusal. Also, individuals who were HIV-tested as part of their TB provider encounter could not be distinguished from patients with documentation of a prior HIV test result.
Routinely-collected public health surveillance datasets are a rich source of information. However, missing data and limited variables are significant hurdles, which can be overcome with data collection improvements. Since the time of this study, the NYC TB surveillance registry has been expanded to collect the date of HIV testing encounter, capture multiple testing encounters, and record all of a patient's TB providers, which will allow for future analyses involving the assessment of time-to-HIV testing, describe multiple testing encounters and estimates of HIV seroconversion during TB treatment.
The TB Registry did not capture the reasons why a patient refused an HIV test. Future studies evaluating HIV testing should include patient interviews to identify potential points of intervention to increase HIV test acceptance.
Despite these limitations, this study not only examines the association between TB providers and successful HIV testing of TB patients in the ART era, but specifically addresses the failure to offer HIV testing and HIV test refusal as two separate outcomes and directionality of TB provider engagement. The setting for the study, NYC, is ideal because of its high HIV and TB prevalence and strong surveillance infrastructure for the longitudinal follow-up of patients. The diverse TB patient population NYC allows these results to be generalizable to other urban centers within the US. This study is an improvement upon prior analyses of TB provider adherence to HIV testing recommendations because of its recognition of the fact that patients can change TB providers during the course of treatment.
Nearly 25 % of TB patients in NYC in 2001-2007 were not tested for HIV, despite national guidelines that all TB patients be tested for HIV. This analysis showed that HIV testing behaviors were associated with a patient's provider type and whether or not the patient changed provider type during the course of treatment. While only 3 % of patients were not offered an HIV test, 64 % of those who were not offered testing first engaged in care with a private TB provider. Efforts must be made to ensure that all TB patients are offered an HIV test by their providers.
Although refusal of HIV testing by TB patients was not found to be strongly associated with provider type, 28 % of patients offered HIV testing refused the test. A better understanding of the barriers to HIV testing and why TB patients refuse HIV testing is needed to improve HIV testing acceptance. Educational campaigns for TB patients can emphasize the relationship between TB and HIV in disease progression, as well as describe treatment options and support services available for HIV-infected persons.
Recent modifications of HIV testing legislation in New York State to allow for routine, opt-out HIV testing without separate written consent may further increase HIV test acceptance. For the duration of this study until 2010, New York State required written informed consent for HIV testing, despite the HIV testing recommendations by the CDC in 2006 supporting routine, opt-out HIV testing and a waiver of separate written consent in clinical settings [31] . Written informed consent procedures can act as a barrier to routine HIV testing in clinical settings [24, 26, 32] . An increase in HIV testing has been observed in states that have changed their HIV testing guidelines, removing requirements for separate written informed consent [33, 34] . Additionally, the presentation of HIV testing in an ''opt-in'' rather than an ''opt-out'' fashion could influence HIV testing acceptance by patients.
Both private and public providers should strongly urge all of their patients to accept HIV testing. Traditional riskbased HIV testing often fails to identify HIV-infected individuals and is not an acceptable testing protocol in a population of TB patients who are inherently at an increased risk for HIV acquisition [35] . Educational campaigns for providers, both private and public, must emphasize the necessity of HIV testing for all TB patients, regardless of the patient's actual or provider-perceived risk profile.
